Gyre Therapeutics (GYRE) Financials

$8.74 -0.52 (-5.62%)

As of 11:35 AM Eastern

Annual Income Statements for Gyre Therapeutics

This table shows Gyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	2.30	-93	12
Consolidated Net Income / (Loss)	4.31	-85	18
Net Income / (Loss) Continuing Operations	4.31	-85	18
Total Pre-Tax Income	9.41	-77	23
Total Operating Income	9.20	-67	16
Total Gross Profit	97	109	102
Total Revenue	102	113	106
Operating Revenue	102	113	106
Total Cost of Revenue	4.79	4.64	3.88
Operating Cost of Revenue	4.79	4.64	3.88
Total Operating Expenses	88	176	86
Selling, General & Admin Expense	17	15	16
Marketing Expense	54	61	58
Research & Development Expense	17	97	12
Other Operating Expenses / (Income)	-	2.71	0.00
Other Special Charges / (Income)	0.00	0.63	0.07
Total Other Income / (Expense), net	0.21	-9.74	7.06
Interest Expense	-0.73	-1.04	-1.55
Other Income / (Expense), net	-0.52	-11	5.51
Income Tax Expense	5.10	8.52	5.32
Net Income / (Loss) Attributable to Noncontrolling Interest	2.01	7.45	5.81
Basic Earnings per Share	$0.04	($1.41)	$0.14
Weighted Average Basic Shares Outstanding	63.59M	65.83M	85.09M
Diluted Earnings per Share	$0.03	($1.41)	$0.05
Weighted Average Diluted Shares Outstanding	75.69M	65.83M	102.29M
Weighted Average Basic & Diluted Shares Outstanding	37.76M	85.42M	93.61M

This table shows Gyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-4.88	-30	2.24	1.85	3.98	-101	7.53	3.53	1.12	-0.10
Consolidated Net Income / (Loss)	-4.88	-28	4.22	3.77	7.51	-101	9.94	4.54	2.86	0.57
Net Income / (Loss) Continuing Operations	-4.88	-28	4.22	3.77	7.51	-101	9.94	4.54	2.86	0.57
Total Pre-Tax Income	-4.88	-23	6.27	5.85	11	-100	12	6.04	3.93	0.77
Total Operating Income	-5.17	-22	6.66	4.97	13	-92	8.07	3.26	4.23	0.60
Total Gross Profit	0.00	98	24	28	31	26	26	24	25	27
Total Revenue	0.00	101	25	29	32	27	27	25	25	28
Operating Revenue	0.00	101	25	29	32	27	27	25	25	28
Total Cost of Revenue	0.00	4.00	1.13	1.08	1.18	1.25	0.98	0.77	0.96	1.18
Operating Cost of Revenue	0.00	4.00	1.13	1.08	1.18	1.25	0.98	0.77	0.96	1.18
Total Operating Expenses	5.17	120	17	23	19	117	18	21	20	26
Selling, General & Admin Expense	4.36	4.17	1.74	1.71	1.16	10	3.40	3.42	3.82	5.46
Marketing Expense	-	-	13	18	14	16	13	14	14	17
Research & Development Expense	0.80	4.31	2.64	3.57	3.01	88	2.18	3.36	2.78	3.71
Total Other Income / (Expense), net	0.28	-0.34	-0.39	0.88	-1.05	-9.17	4.41	2.84	-0.30	0.11
Interest Expense	-0.28	-0.18	-0.18	-0.25	-0.28	-0.33	-0.33	-0.35	-0.52	-0.35
Other Income / (Expense), net	-	-	-0.58	0.63	-1.33	-9.50	4.08	2.49	-0.83	-0.24
Income Tax Expense	0.00	5.10	2.05	2.08	3.68	0.70	2.55	1.50	1.07	0.20
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	1.97	1.92	3.53	0.03	2.40	1.01	1.73	0.67
Weighted Average Basic Shares Outstanding	31.48M	63.59M	63.59M	63.59M	63.59M	65.83M	83.27M	85.50M	85.64M	85.09M
Weighted Average Diluted Shares Outstanding	31.48M	75.69M	78.92M	78.90M	78.90M	65.83M	102.59M	104.33M	102.64M	102.29M
Weighted Average Basic & Diluted Shares Outstanding	31.49M	37.76M	37.76M	37.97M	37.98M	85.42M	85.51M	93.42M	93.52M	93.61M

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-5.03	8.33	-22
Net Cash From Operating Activities	11	26	-3.64
Net Cash From Continuing Operating Activities	11	26	-3.64
Net Income / (Loss) Continuing Operations	4.31	-85	18
Consolidated Net Income / (Loss)	4.31	-85	18
Depreciation Expense	1.09	1.07	1.55
Amortization Expense	0.04	0.04	0.04
Non-Cash Adjustments To Reconcile Net Income	14	105	-11
Changes in Operating Assets and Liabilities, net	-8.64	4.76	-13
Net Cash From Investing Activities	-14	-20	-20
Net Cash From Continuing Investing Activities	-14	-20	-20
Purchase of Property, Plant & Equipment	-4.99	-8.52	-2.32
Acquisitions	-1.35	-1.19	-2.50
Sale of Property, Plant & Equipment	0.00	0.66	0.40
Divestitures	0.00	5.59	0.00
Other Investing Activities, net	-7.48	-16	-15
Net Cash From Financing Activities	0.00	2.50	2.10
Net Cash From Continuing Financing Activities	0.00	2.50	2.10
Repayment of Debt	-	-	0.00
Repurchase of Preferred Equity	0.00	2.50	0.00
Issuance of Common Equity	-	0.00	0.77
Other Financing Activities, net	-	0.00	1.33
Effect of Exchange Rate Changes	-1.89	-0.30	-0.27
Cash Income Taxes Paid	6.31	6.35	8.52

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-52	16	2.97	-4.42	2.35	7.43	-3.72	-14	-0.23	-4.05
Net Cash From Operating Activities	-7.28	42	10	4.53	7.58	3.36	2.88	-5.49	1.73	-2.76
Net Cash From Continuing Operating Activities	-7.28	42	10	4.53	7.58	3.36	2.88	-5.49	1.73	-2.76
Net Income / (Loss) Continuing Operations	-4.88	-28	4.22	3.77	7.51	-101	9.94	4.54	2.86	0.57
Consolidated Net Income / (Loss)	-4.88	-28	4.22	3.77	7.51	-101	9.94	4.54	2.86	0.57
Depreciation Expense	0.04	0.87	0.28	0.31	0.19	0.30	0.42	0.23	0.45	0.46
Amortization Expense	-	-	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Non-Cash Adjustments To Reconcile Net Income	0.33	70	0.29	0.55	0.69	104	-4.41	-2.67	0.15	-3.61
Changes in Operating Assets and Liabilities, net	-2.77	-0.43	5.63	-0.10	-0.82	0.06	-3.06	-7.60	-1.73	-0.18
Net Cash From Investing Activities	-	-69	-7.65	-8.05	-5.40	1.34	-7.22	-8.27	-2.39	-2.00
Net Cash From Continuing Investing Activities	-	-69	-7.65	-8.05	-5.40	1.34	-7.22	-8.27	-2.39	-2.00
Purchase of Property, Plant & Equipment	-	-	-1.74	-2.48	-1.97	-2.32	-0.23	-1.46	-0.69	0.07
Acquisitions	-	-	-0.07	-0.00	-0.00	-1.13	0.00	-	-0.00	-2.50
Sale of Property, Plant & Equipment	-	-0.45	0.00	0.13	0.36	0.17	0.05	0.22	-0.01	0.14
Other Investing Activities, net	-	-60	-5.84	-5.71	-2.79	-1.97	-7.04	-7.04	-1.69	0.29
Net Cash From Financing Activities	-45	45	0.00	-	-	2.50	0.66	0.16	0.32	0.96
Net Cash From Continuing Financing Activities	-45	45	0.00	-	-	2.50	0.66	0.16	0.32	0.96
Other Financing Activities, net	0.00	-	0.00	-	-	-	0.66	0.28	0.37	0.02
Cash Income Taxes Paid	-	-	0.46	3.54	1.38	0.96	1.44	5.78	0.54	0.76

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	85	117	125
Total Current Assets	50	57	65
Cash & Equivalents	25	34	12
Short-Term Investments	-	0.00	15
Note & Lease Receivable	17	0.39	9.33
Accounts Receivable	0.00	16	20
Inventories, net	6.12	4.28	6.34
Prepaid Expenses	0.38	1.55	1.19
Other Current Assets	0.84	1.05	1.44
Plant, Property, & Equipment, net	18	23	24
Total Noncurrent Assets	17	36	37
Noncurrent Note & Lease Receivables	0.00	4.72	0.00
Intangible Assets	0.30	0.21	0.27
Noncurrent Deferred & Refundable Income Taxes	4.08	4.70	5.62
Other Noncurrent Operating Assets	13	26	31
Total Liabilities & Shareholders' Equity	85	117	125
Total Liabilities	13	38	27
Total Current Liabilities	12	20	20
Accounts Payable	0.12	0.36	0.11
Accrued Expenses	9.26	12	11
Current Deferred Revenue	0.15	0.00	0.00
Current Deferred & Payable Income Tax Liabilities	2.10	5.05	2.83
Other Current Liabilities	0.61	2.70	5.96
Total Noncurrent Liabilities	0.29	18	7.49
Noncurrent Deferred Revenue	0.12	0.21	0.93
Other Noncurrent Operating Liabilities	0.18	18	6.56
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	65	0.00
Total Equity & Noncontrolling Interests	72	14	98
Total Preferred & Common Equity	43	-16	63
Total Common Equity	43	-16	63
Common Stock	33	68	136
Retained Earnings	7.40	-86	-73
Accumulated Other Comprehensive Income / (Loss)	-0.39	-1.64	-2.60
Other Equity Adjustments	2.66	3.10	3.10
Noncontrolling Interest	30	30	35

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	31	19	12	9.96	122	121	125
Total Current Assets	30	14	7.62	5.13	63	54	55
Cash & Equivalents	23	8.10	6.92	2.23	30	16	16
Short-Term Investments	0.00	-	-	-	7.57	9.00	9.23
Note & Lease Receivable	-	-	-	-	15	19	19
Accounts Receivable	5.00	5.00	0.00	1.20	1.29	1.29	1.29
Inventories, net	-	-	-	-	4.94	5.64	6.38
Prepaid Expenses	2.16	0.92	0.70	1.70	1.79	1.15	1.05
Other Current Assets	-	-	-	-	1.90	1.72	1.51
Plant, Property, & Equipment, net	0.12	0.00	0.00	0.00	24	24	24
Total Noncurrent Assets	0.65	4.74	4.77	4.83	36	44	46
Noncurrent Note & Lease Receivables	-	4.55	4.61	4.66	4.78	4.84	4.90
Intangible Assets	-	-	-	-	0.20	0.19	0.18
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	5.00	5.08	5.16
Other Noncurrent Operating Assets	0.65	0.19	0.17	0.17	26	34	36
Total Liabilities & Shareholders' Equity	31	19	12	9.96	122	121	125
Total Liabilities	1.64	11	7.40	6.45	33	28	27
Total Current Liabilities	1.64	6.84	2.79	1.78	19	16	15
Accounts Payable	0.04	0.02	0.01	0.16	0.33	0.27	0.30
Accrued Expenses	0.18	0.74	2.07	0.92	11	11	9.55
Current Deferred Revenue	0.00	-	-	-	0.04	0.06	0.04
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	6.47	2.26	2.84
Other Current Liabilities	0.38	5.00	0.00	0.00	1.88	2.47	1.98
Total Noncurrent Liabilities	0.00	4.55	4.61	4.66	14	12	12
Noncurrent Deferred Revenue	-	-	-	-	0.20	0.19	0.19
Other Noncurrent Operating Liabilities	0.00	4.55	4.61	4.66	14	12	12
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	33	33	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	29	-26	-28	3.52	89	93	98
Total Preferred & Common Equity	29	-26	-28	3.52	57	60	63
Total Common Equity	29	-26	-28	-30	57	60	63
Common Stock	400	385	385	385	133	134	134
Retained Earnings	-370	-411	-413	-415	-78	-74	-73
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-1.74	-2.01	-0.95
Other Equity Adjustments	-	-	-	-	3.10	3.10	3.10
Noncontrolling Interest	-	-	-	-	32	33	35

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	1,293.98%	10.91%	-6.78%
EBITDA Growth	111.20%	-883.44%	130.25%
EBIT Growth	109.88%	-998.10%	127.78%
NOPAT Growth	106.86%	-1,215.66%	126.48%
Net Income Growth	104.91%	-2,081.46%	120.94%
EPS Growth	101.05%	-4,800.00%	103.55%
Operating Cash Flow Growth	112.75%	142.50%	-114.06%
Free Cash Flow Firm Growth	21.12%	7.41%	68.20%
Invested Capital Growth	916.42%	-4.42%	59.53%
Revenue Q/Q Growth	3,062.96%	-39.59%	0.69%
EBITDA Q/Q Growth	-16.00%	-2,244.91%	128.68%
EBIT Q/Q Growth	-23.47%	-4,116.94%	126.26%
NOPAT Q/Q Growth	-62.84%	-0.25%	123.40%
Net Income Q/Q Growth	-63.70%	-589.30%	121.40%
EPS Q/Q Growth	-92.11%	-58.43%	103.42%
Operating Cash Flow Q/Q Growth	121.66%	-60.06%	-246.99%
Free Cash Flow Firm Q/Q Growth	-3,916.64%	-7.24%	88.59%
Invested Capital Q/Q Growth	648.48%	3,388.36%	-2.25%
Profitability Metrics	-	-	-
Gross Margin	95.31%	95.91%	96.33%
EBITDA Margin	9.60%	-67.78%	21.99%
Operating Margin	9.00%	-59.26%	15.28%
EBIT Margin	8.49%	-68.76%	20.49%
Profit (Net Income) Margin	4.22%	-75.35%	16.92%
Tax Burden Percent	45.84%	111.06%	77.09%
Interest Burden Percent	108.36%	98.66%	107.14%
Effective Tax Rate	54.16%	0.00%	22.91%
Return on Invested Capital (ROIC)	20.44%	-102.30%	21.35%
ROIC Less NNEP Spread (ROIC-NNEP)	20.17%	28.64%	3.28%
Return on Net Nonoperating Assets (RNNOA)	-12.82%	-11.15%	-1.12%
Return on Equity (ROE)	7.61%	-113.45%	20.24%
Cash Return on Invested Capital (CROIC)	-103.28%	-97.78%	-24.52%
Operating Return on Assets (OROA)	12.37%	-77.51%	17.91%
Return on Assets (ROA)	6.14%	-84.93%	14.80%
Return on Common Equity (ROCE)	5.62%	-20.10%	5.43%
Return on Equity Simple (ROE_SIMPLE)	10.15%	540.06%	28.27%
Net Operating Profit after Tax (NOPAT)	4.22	-47	12
NOPAT Margin	4.12%	-41.48%	11.78%
Net Nonoperating Expense Percent (NNEP)	0.27%	-130.94%	18.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-337.38%	12.66%
Cost of Revenue to Revenue	4.69%	4.09%	3.67%
SG&A Expenses to Revenue	16.98%	12.92%	15.23%
R&D to Revenue	16.31%	85.40%	11.37%
Operating Expenses to Revenue	86.32%	155.17%	81.04%
Earnings before Interest and Taxes (EBIT)	8.69	-78	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	9.82	-77	23
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.39	0.00	17.87
Price to Tangible Book Value (P/TBV)	0.39	0.00	17.95
Price to Revenue (P/Rev)	0.16	8.60	10.70
Price to Earnings (P/E)	7.22	0.00	93.64
Dividend Yield	271.09%	0.00%	0.00%
Earnings Yield	13.86%	0.00%	1.07%
Enterprise Value to Invested Capital (EV/IC)	0.45	23.05	15.89
Enterprise Value to Revenue (EV/Rev)	0.21	9.14	10.78
Enterprise Value to EBITDA (EV/EBITDA)	2.15	0.00	49.01
Enterprise Value to EBIT (EV/EBIT)	2.43	0.00	52.61
Enterprise Value to NOPAT (EV/NOPAT)	5.01	0.00	91.50
Enterprise Value to Operating Cash Flow (EV/OCF)	1.98	40.03	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.64	-0.39	-0.34
Leverage Ratio	1.24	1.34	1.37
Compound Leverage Factor	1.34	1.32	1.47
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	41.12%	120.17%	35.65%
Common Equity to Total Capital	58.88%	-20.17%	64.35%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	2.99	13.50	26.17
Noncontrolling Interest Sharing Ratio	26.21%	82.29%	73.15%
Liquidity Ratios	-	-	-
Current Ratio	4.06	2.85	3.32
Quick Ratio	3.46	2.51	2.86
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-49	-45	-14
Operating Cash Flow to CapEx	214.18%	329.71%	-190.23%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	1.46	1.13	0.87
Accounts Receivable Turnover	0.00	0.00	5.83
Inventory Turnover	0.00	0.89	0.73
Fixed Asset Turnover	10.95	5.53	4.48
Accounts Payable Turnover	1.47	19.44	16.78
Days Sales Outstanding (DSO)	0.00	0.00	62.59
Days Inventory Outstanding (DIO)	0.00	409.52	498.91
Days Payable Outstanding (DPO)	249.06	18.78	21.76
Cash Conversion Cycle (CCC)	-249.06	390.75	539.75
Capital & Investment Metrics	-	-	-
Invested Capital	47	45	72
Invested Capital Turnover	4.96	2.47	1.81
Increase / (Decrease) in Invested Capital	53	-2.08	27
Enterprise Value (EV)	21	1,036	1,140
Market Capitalization	17	976	1,132
Book Value per Share	$1.35	($0.42)	$0.68
Tangible Book Value per Share	$1.34	($0.42)	$0.67
Total Capital	72	78	98
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-25	-34	-27
Capital Expenditures (CapEx)	4.99	7.85	1.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)	12	3.67	19
Debt-free Net Working Capital (DFNWC)	37	37	45
Net Working Capital (NWC)	37	37	45
Net Nonoperating Expense (NNE)	-0.10	38	-5.44
Net Nonoperating Obligations (NNO)	-25	-34	-27
Total Depreciation and Amortization (D&A)	1.13	1.11	1.59
Debt-free, Cash-free Net Working Capital to Revenue	11.96%	3.23%	17.59%
Debt-free Net Working Capital to Revenue	36.57%	32.77%	42.81%
Net Working Capital to Revenue	36.57%	32.77%	42.81%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.26)	($1.41)	$0.14
Adjusted Weighted Average Basic Shares Outstanding	31.55M	65.83M	85.09M
Adjusted Diluted Earnings per Share	($0.26)	($1.41)	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	31.55M	65.83M	102.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.76M	85.42M	93.61M
Normalized Net Operating Profit after Tax (NOPAT)	6.44	-47	13
Normalized NOPAT Margin	6.30%	-41.09%	11.83%
Pre Tax Income Margin	9.20%	-67.84%	21.95%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	4,059.67%	3,039.92%	0.00%	0.00%	-73.25%	8.99%	-13.99%	-20.45%	2.67%
EBITDA Growth	79.61%	-6.91%	143.69%	-88.52%	326.94%	-366.92%	97.36%	1.18%	-66.81%	100.82%
EBIT Growth	79.52%	-10.57%	141.41%	-89.13%	321.27%	-350.27%	99.66%	2.68%	-70.20%	100.35%
NOPAT Growth	79.52%	-10.57%	143.55%	-93.78%	336.93%	-307.98%	43.37%	-23.43%	-64.10%	100.69%
Net Income Growth	80.65%	-37.23%	129.01%	-92.70%	253.77%	-261.95%	135.59%	20.37%	-61.97%	100.56%
EPS Growth	80.00%	-54.69%	106.52%	-98.78%	131.25%	-52.53%	0.00%	-50.00%	-80.00%	0.00%
Operating Cash Flow Growth	66.31%	339.30%	186.45%	136.87%	204.19%	-92.06%	-72.31%	-221.18%	-77.24%	-182.08%
Free Cash Flow Firm Growth	42.62%	-379.70%	54.13%	-81.08%	199.06%	9.43%	-1,723.13%	-869.62%	-608.83%	57.58%
Invested Capital Growth	265.74%	916.42%	90.39%	-152.56%	-79.49%	-4.42%	7,020.46%	3,639.73%	5,592.94%	59.53%
Revenue Q/Q Growth	0.00%	0.00%	-75.44%	17.64%	9.25%	-15.27%	-54.09%	-7.17%	1.04%	9.35%
EBITDA Q/Q Growth	-109.93%	-321.24%	129.51%	-7.09%	96.47%	-966.69%	116.51%	-52.37%	-35.55%	-78.53%
EBIT Q/Q Growth	-110.03%	-334.77%	127.10%	-7.95%	104.02%	-984.70%	115.73%	-52.66%	-40.78%	-89.49%
NOPAT Q/Q Growth	-107.02%	-334.77%	128.50%	-28.52%	167.47%	-848.64%	111.88%	-61.82%	25.41%	-85.70%
Net Income Q/Q Growth	-109.46%	-471.21%	115.12%	-10.60%	99.20%	-1,444.57%	110.81%	-54.32%	-37.06%	-80.08%
EPS Q/Q Growth	-109.76%	-518.75%	103.03%	-33.33%	150.00%	-3,120.00%	102.11%	-66.67%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	40.81%	681.26%	-75.37%	-56.48%	67.26%	-55.68%	-92.37%	-290.46%	131.42%	-259.79%
Free Cash Flow Firm Q/Q Growth	-129.45%	-400.44%	96.34%	450.75%	54.15%	-557.58%	12.03%	-48.07%	-1.91%	61.86%
Invested Capital Q/Q Growth	71.35%	648.48%	-101.58%	-159.49%	166.86%	3,388.36%	14.35%	32.73%	7.53%	-2.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	96.06%	95.49%	96.33%	96.30%	95.40%	96.40%	96.95%	96.24%	95.78%
EBITDA Margin	0.00%	-21.27%	25.56%	20.19%	36.31%	-371.38%	46.29%	23.75%	15.15%	2.97%
Operating Margin	0.00%	-22.13%	26.73%	16.96%	39.84%	-337.53%	29.70%	12.93%	16.61%	2.14%
EBIT Margin	0.00%	-22.13%	24.42%	19.10%	35.68%	-372.51%	44.73%	22.81%	13.37%	1.28%
Profit (Net Income) Margin	0.00%	-27.49%	16.91%	12.85%	23.44%	-371.95%	36.56%	17.99%	11.21%	2.04%
Tax Burden Percent	100.00%	122.36%	67.25%	64.40%	67.13%	100.70%	79.60%	75.19%	72.67%	73.70%
Interest Burden Percent	94.54%	101.51%	103.02%	104.48%	97.87%	99.16%	102.70%	104.90%	115.35%	215.64%
Effective Tax Rate	0.00%	0.00%	32.75%	35.60%	32.87%	0.00%	20.40%	24.81%	27.33%	26.30%
Return on Invested Capital (ROIC)	0.00%	-76.77%	0.00%	1,955.34%	1,326.02%	-582.67%	107.96%	32.72%	33.95%	2.86%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-42.96%	0.00%	1,953.96%	1,334.38%	-457.13%	92.51%	19.70%	35.57%	2.43%
Return on Net Nonoperating Assets (RNNOA)	0.00%	27.31%	0.00%	-1,913.52%	-1,027.11%	178.02%	-43.74%	-6.42%	-9.53%	-0.83%
Return on Equity (ROE)	0.00%	-49.46%	133.95%	41.82%	298.91%	-404.65%	64.22%	26.31%	24.43%	2.03%
Cash Return on Invested Capital (CROIC)	20.25%	-103.28%	0.00%	0.00%	-1,107.71%	-97.78%	-191.05%	-172.10%	-335.71%	-24.52%
Operating Return on Assets (OROA)	0.00%	-32.24%	104.59%	62.14%	326.95%	-419.90%	73.52%	38.18%	20.77%	1.12%
Return on Assets (ROA)	0.00%	-40.05%	72.46%	41.81%	214.80%	-419.27%	60.10%	30.11%	17.41%	1.78%
Return on Common Equity (ROCE)	0.00%	-36.50%	4.40%	25.25%	-3.79%	-71.68%	20.50%	8.57%	8.00%	0.55%
Return on Equity Simple (ROE_SIMPLE)	40.45%	0.00%	-88.88%	87.57%	-352.60%	0.00%	-140.82%	-130.89%	-132.40%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.62	-16	4.48	3.20	8.57	-64	6.42	2.45	3.08	0.44
NOPAT Margin	0.00%	-15.49%	17.97%	10.92%	26.74%	-236.27%	23.64%	9.72%	12.07%	1.58%
Net Nonoperating Expense Percent (NNEP)	-2.89%	-33.81%	-1.23%	1.38%	-8.36%	-125.54%	15.45%	13.02%	-1.61%	0.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-459.84%	-	-	-	0.45%
Cost of Revenue to Revenue	0.00%	3.94%	4.51%	3.67%	3.70%	4.60%	3.60%	3.05%	3.76%	4.22%
SG&A Expenses to Revenue	0.00%	4.11%	6.98%	5.83%	3.61%	37.04%	12.51%	13.57%	15.00%	19.60%
R&D to Revenue	0.00%	4.25%	10.57%	12.17%	9.39%	322.94%	8.03%	13.30%	10.89%	13.32%
Operating Expenses to Revenue	0.00%	118.20%	68.76%	79.37%	58.11%	430.99%	66.69%	84.29%	79.63%	93.39%
Earnings before Interest and Taxes (EBIT)	-5.17	-22	6.09	5.60	11	-101	12	5.75	3.41	0.36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.13	-22	6.37	5.92	12	-101	13	5.99	3.86	0.83
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.54	0.39	0.00	0.00	0.00	0.00	26.36	16.90	18.54	17.87
Price to Tangible Book Value (P/TBV)	0.54	0.39	0.00	0.00	0.00	0.00	26.45	16.96	18.60	17.95
Price to Revenue (P/Rev)	4.91	0.16	0.06	0.09	0.10	8.60	12.91	9.14	11.15	10.70
Price to Earnings (P/E)	1.34	7.22	0.41	0.00	0.00	0.00	0.00	0.00	0.00	93.64
Dividend Yield	283.73%	271.09%	690.82%	406.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	74.90%	13.86%	244.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.07%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.45	0.00	0.00	38.32	23.05	28.94	15.06	16.10	15.89
Enterprise Value to Revenue (EV/Rev)	0.00	0.21	0.26	0.25	0.26	9.14	12.86	9.21	11.25	10.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	2.15	1.04	0.00	13.78	0.00	0.00	0.00	0.00	49.01
Enterprise Value to EBIT (EV/EBIT)	0.00	2.43	1.08	0.00	25.44	0.00	0.00	0.00	0.00	52.61
Enterprise Value to NOPAT (EV/NOPAT)	0.00	5.01	1.42	0.00	0.00	0.00	0.00	0.00	0.00	91.50
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	1.98	1.00	0.79	0.76	40.03	81.05	123.37	477.09	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	2.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.97	-0.64	-1.25	-0.98	-0.77	-0.39	-0.47	-0.33	-0.27	-0.34
Leverage Ratio	1.22	1.24	1.71	1.14	1.25	1.34	1.46	1.36	1.33	1.37
Compound Leverage Factor	1.15	1.26	1.77	1.19	1.22	1.32	1.50	1.42	1.53	2.95
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	947.09%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	41.12%	452.81%	666.85%	0.00%	120.17%	36.20%	35.35%	35.84%	35.65%
Common Equity to Total Capital	100.00%	58.88%	-352.81%	-566.85%	-847.09%	-20.17%	63.80%	64.65%	64.16%	64.35%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-10.27	1.78	-21.98	-31.07	-33.53	12.84	27.76	22.78	26.75	25.61
Noncontrolling Interest Sharing Ratio	0.00%	26.21%	96.72%	39.63%	101.27%	82.29%	68.08%	67.42%	67.26%	73.15%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	18.40	4.06	2.05	2.73	2.88	2.85	3.22	3.44	3.72	3.32
Quick Ratio	17.09	3.46	1.91	2.48	1.92	2.51	2.78	2.89	3.12	2.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-69	-2.51	8.80	14	-62	-46	-68	-69	-26
Operating Cash Flow to CapEx	0.00%	9,462.64%	597.99%	193.47%	470.64%	155.77%	1,593.37%	-443.70%	247.28%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.06	1.46	4.28	3.25	9.16	1.13	1.64	1.67	1.55	0.87
Accounts Receivable Turnover	1.06	0.00	45.44	0.00	60.58	0.00	36.80	0.00	84.47	5.83
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.89	0.00	0.00	0.00	0.73
Fixed Asset Turnover	5.32	10.95	294.70	0.00	0.00	5.53	9.82	0.00	0.00	4.48
Accounts Payable Turnover	1.67	1.47	2.17	11.89	74.18	19.44	25.95	30.31	17.17	16.78
Days Sales Outstanding (DSO)	345.02	0.00	8.03	0.00	6.03	0.00	9.92	0.00	4.32	62.59
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	409.52	0.00	0.00	0.00	498.91
Days Payable Outstanding (DPO)	219.03	249.06	168.31	30.69	4.92	18.78	14.06	12.04	21.26	21.76
Cash Conversion Cycle (CCC)	125.99	-249.06	-160.28	-30.69	1.10	390.75	-4.15	-12.04	-16.94	539.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	6.29	47	-0.74	-1.93	1.29	45	51	68	73	72
Invested Capital Turnover	2.59	4.96	-29.83	179.03	49.59	2.47	4.57	3.37	2.81	1.81
Increase / (Decrease) in Invested Capital	10	53	6.99	-5.60	-5.00	-2.08	52	70	72	27
Enterprise Value (EV)	-7.23	21	33	40	49	1,036	1,488	1,028	1,182	1,140
Market Capitalization	16	17	7.82	13	18	976	1,493	1,020	1,172	1,132
Book Value per Share	$0.93	$1.35	($0.69)	($0.75)	($0.78)	($0.42)	$0.66	$0.71	$0.68	$0.68
Tangible Book Value per Share	$0.93	$1.34	($0.69)	($0.75)	($0.78)	($0.42)	$0.66	$0.70	$0.67	$0.67
Total Capital	29	72	7.36	5.00	3.52	78	89	93	98	98
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-23	-25	-8.10	-6.92	-2.23	-34	-37	-25	-25	-27
Capital Expenditures (CapEx)	0.00	0.45	1.74	2.34	1.61	2.16	0.18	1.24	0.70	-0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	5.51	12	-0.93	-2.10	1.12	3.67	5.89	13	15	19
Debt-free Net Working Capital (DFNWC)	29	37	7.17	4.83	3.35	37	43	38	40	45
Net Working Capital (NWC)	29	37	7.17	4.83	3.35	37	43	38	40	45
Net Nonoperating Expense (NNE)	1.27	12	0.26	-0.57	1.06	37	-3.51	-2.09	0.22	-0.13
Net Nonoperating Obligations (NNO)	-23	-25	-8.10	-6.92	-2.23	-34	-37	-25	-25	-27
Total Depreciation and Amortization (D&A)	0.04	0.87	0.29	0.32	0.20	0.31	0.43	0.24	0.45	0.47
Debt-free, Cash-free Net Working Capital to Revenue	170.44%	11.96%	-0.73%	-1.35%	0.60%	3.23%	5.09%	11.51%	14.28%	17.59%
Debt-free Net Working Capital to Revenue	884.42%	36.57%	5.67%	3.10%	1.78%	32.77%	37.37%	34.00%	38.17%	42.81%
Net Working Capital to Revenue	884.42%	36.57%	5.67%	3.10%	1.78%	32.77%	37.37%	34.00%	38.17%	42.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	($0.98)	$0.01	($0.07)	($0.04)	($1.54)	$0.09	$0.04	$0.01	$0.00
Adjusted Weighted Average Basic Shares Outstanding	31.48M	63.59M	37.76M	37.80M	37.98M	65.83M	83.27M	85.50M	85.64M	85.09M
Adjusted Diluted Earnings per Share	($0.16)	($0.99)	$0.01	($0.07)	($0.04)	($1.51)	$0.03	$0.01	$0.01	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	31.48M	75.69M	37.98M	37.80M	37.98M	65.83M	102.59M	104.33M	102.64M	102.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.49M	37.76M	37.76M	37.97M	37.98M	85.42M	85.51M	93.42M	93.52M	93.61M
Normalized Net Operating Profit after Tax (NOPAT)	-3.62	24	4.48	3.20	8.92	-64	6.42	2.50	3.08	0.44
Normalized NOPAT Margin	0.00%	23.99%	17.97%	10.92%	27.84%	-236.27%	23.64%	9.93%	12.07%	1.58%
Pre Tax Income Margin	0.00%	-22.46%	25.15%	19.96%	34.92%	-369.38%	45.93%	23.92%	15.42%	2.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	378.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	378.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Gyre Therapeutics' Financials

When does Gyre Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Gyre Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gyre Therapeutics' net income changed over the last 2 years?

Gyre Therapeutics' net income appears to be on a downward trend, with a most recent value of $17.90 million in 2024, rising from $4.31 million in 2022. The previous period was -$85.48 million in 2023. Find out what analysts predict for Gyre Therapeutics in the coming months.

What is Gyre Therapeutics's operating income?

Gyre Therapeutics's total operating income in 2024 was $16.16 million, based on the following breakdown:

Total Gross Profit: $101.87 million
Total Operating Expenses: $85.71 million

How has Gyre Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Gyre Therapeutics' total revenue changed from $102.29 million in 2022 to $105.76 million in 2024, a change of 3.4%.

How much debt does Gyre Therapeutics have?

Gyre Therapeutics' total liabilities were at $27.00 million at the end of 2024, a 29.1% decrease from 2023, and a 115.4% increase since 2022.

How much cash does Gyre Therapeutics have?

In the past 2 years, Gyre Therapeutics' cash and equivalents has ranged from $11.81 million in 2024 to $33.51 million in 2023, and is currently $11.81 million as of their latest financial filing in 2024.

How has Gyre Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Gyre Therapeutics' book value per share changed from 1.35 in 2022 to 0.68 in 2024, a change of -49.9%.

Related Companies

This page (NASDAQ:GYRE) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Financials

Frequently Asked Questions About Gyre Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Financials

Annual Income Statements for Gyre Therapeutics

Quarterly Income Statements for Gyre Therapeutics

Annual Cash Flow Statements for Gyre Therapeutics

Quarterly Cash Flow Statements for Gyre Therapeutics

Annual Balance Sheets for Gyre Therapeutics

Quarterly Balance Sheets for Gyre Therapeutics

Annual Metrics and Ratios for Gyre Therapeutics

Quarterly Metrics and Ratios for Gyre Therapeutics

Frequently Asked Questions About Gyre Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools